U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07424677) titled 'Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy' on Dec. 26, 2025.

Brief Summary: Study of Saroglitazar Magnesium for PBC Patients with Incomplete Response or Intolerant to UDCA Therapy

Study Start Date: March, 2026

Study Type: INTERVENTIONAL

Condition: Primary Biliary Cholangitis

Intervention: DRUG: Saroglitazar Magnesium 1 mg

Saroglitazar magnesium 1 mg once daily, orally each morning before breakfast

DRUG: Placebo

Matching Placebo once daily, orally each morning before breakfast

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Zydus Therapeutics Inc.

Disclaimer: C...